SCHEMBL4470856

SCHEMBL4470856

O=C1c2ccccc2C(=O)N1CCc1cc2cc(Cl)ccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
LMNA P02545 5/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
TP53 P04637 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
LOXL2 Q9Y4K0 1/20 0.49
HPGD P15428 2/20 0.48
HTT P42858 1/20 0.48
SIRT1 Q96EB6 1/20 0.47
RXFP1 Q9HBX9 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 3/20 0.44
GPR84 Q9NQS5 1/20 0.44
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
DRD2 P14416 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466817 0.89 MAPT (0.43) MAPTLMNAMEN1KMT2ATP53
SCHEMBL12758951 0.85 HRH3 (0.56) MAPTLMNAMEN1KMT2ATDP1
SCHEMBL8837552 0.81 LMNA (0.61) MAPTLMNAMEN1KMT2ALOXL2
SCHEMBL11354778 0.80 GPR84 (0.44) MAPTLMNAMEN1KMT2AHPGD
SCHEMBL8801068 0.77 GPR84 (0.51) MAPTLMNAMEN1KMT2ATP53
SCHEMBL8799883 0.73 HTR1A (0.48) MAPTLMNAMEN1KMT2AHTT
SCHEMBL866136 0.73 LOXL2 (0.72) MAPTLMNAMEN1KMT2ALOXL2
SCHEMBL650217 0.73 MAPT (0.86) MAPTLMNAMEN1KMT2ATP53
Hydrochloric Acid SCHEMBL9461139 0.72 MAPT (0.51) MAPTLMNAMEN1KMT2ATP53
SCHEMBL18669052 0.70 CASP3 (0.65) MAPTMEN1KMT2ATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582771-B2 Process for the synthesis of cPLA2 inhibitors WYETH (US) 2009-09-01 US disclosed
US-7582771-B2 Process for the synthesis of cPLA2 inhibitors WYETH (US) 2009-09-01 US disclosed
US-20050049296-A1 Process for the synthesis of cPLA2 inhibitors WYETH (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049296-A1 Process for the synthesis of cPLA2 inhibitors PLA2G12A, ACOX3, CPA2 MAPT 4856/4885LMNA 1215/4885MEN1 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.